Cubist Obtains Remaining Rights to Ceftolozane from Astellas

[Business Wire] – LEXINGTON, Mass. & TOKYO–(BUSINESSWIRE)– Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Astellas Pharma Inc. (Tokyo: 4503) today announced that they entered into an agreement under which Cubist obtains … more

View todays social media effects on CBST

View the latest stocks trending across Twitter. Click to view dashboard

See who Cubist is hiring next, click here to view